Docoh
Loading...

HALO Halozyme Therapeutics

Employees

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On May 5, 2021, the Company held its Annual Meeting of Stockholders. Of the 143,301,550 shares of the Company's common stock outstanding as of the record date, 127,617,860 shares were represented at the annual meeting.

The stockholders considered five proposals at the meeting, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 26, 2021. The number of votes cast for and against (or withheld) and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below.

Proposal 1: Election of three Class I directors to hold office for a three-year term expiring at the 2023 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified:

NamesVotes ForWithheldBroker Non-Votes
Jean-Pierre Bizzari79,212,26734,831,13713,574,456
James M. Daly76,583,48037,459,92413,574,456


Each of the foregoing candidates were elected and each received affirmative votes from more than a majority of the outstanding shares.

Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows:

Votes ForVotes AgainstAbstainBroker Non-Votes
111,785,4991,966,895291,01013,574,456


The foregoing proposal was approved.

Proposal 3: The vote on a proposal to approve the Halozyme Therapeutics, Inc. 2021 Stock Plan was as follows:

Votes ForVotes AgainstAbstainBroker Non-Votes
111,100,0172,870,38373,00413,574,456


The foregoing proposal was approved.

Proposal 4: The vote on a proposal to approve the Halozyme Therapeutics, Inc. 2021 Employee Stock Purchase Plan was as follows:

Votes ForVotes AgainstAbstainBroker Non-Votes
113,281,764728,83832,80213,574,456


The foregoing proposal was approved

Proposal 5: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021 was as follows:




Votes ForVotes AgainstAbstainBroker Non-Votes
125,868,1371,653,96295,7610


The foregoing proposal was approved.